人工智能药物发现领域的先锋企业南洋生物制药有限公司(Nanyang Biologics Pte. Ltd.)宣布,已与RF Acquisition Corp II签署业务合并协议。这项交易总价值达15亿美元,旨在推进公司的公开上市计划。
通过此次合并协议,南洋生物制药将借助RF Acquisition Corp II的平台实现公开上市目标。该交易标志着这家专注于AI驱动药物研发的创新企业迈出了资本市场化的重要一步。
人工智能药物发现领域的先锋企业南洋生物制药有限公司(Nanyang Biologics Pte. Ltd.)宣布,已与RF Acquisition Corp II签署业务合并协议。这项交易总价值达15亿美元,旨在推进公司的公开上市计划。
通过此次合并协议,南洋生物制药将借助RF Acquisition Corp II的平台实现公开上市目标。该交易标志着这家专注于AI驱动药物研发的创新企业迈出了资本市场化的重要一步。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.